REPUPOSING OF CYCLIN DEPENDENT KINASE INHIBITOR ABEMACICLIB FOR STROCK TREATMENT

This review examines the repurposing of established pharmacotherapies for the treatment of ischemic stroke, specifically ticagrelor and abemaciclib. Ticagrelor, reacts to platelet responsibility and increases cerebral blood flow, 1.000 dependent ligand is confirmed, ABEMACICLIB-Dick Strong bondage-attraction shows, indicating its ability to modulate Galactosidase Alpha activity, suitable for conditions that can complicate stroke outcomes Analysis also reveals promising strategies, including cangrelor and tedizolid, suggesting a diverse range of therapies to improve stroke management Structural analysis of protein-ligand interactions Provide insights into manufacturing optimization about and highlights the effectiveness of existing drugs in new clinical settings Findings advocate further experimental verification of the efficacy and safety of these recycled drugs